[Federal Register Volume 89, Number 125 (Friday, June 28, 2024)]
[Notices]
[Pages 54047-54051]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-14195]



[[Page 54047]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 22-54]


Michael Gore, P.A.; Decision and Order

    On August 26, 2022, the Drug Enforcement Administration (DEA or 
Government) issued an Order to Show Cause (OSC) to Michael Gore, P.A., 
(Respondent) of Staten Island, New York. OSC, at 1, 8. The OSC proposed 
the revocation of Respondent's DEA Certificate of Registration, Control 
No. MG1185277, alleging that Respondent's continued registration is 
inconsistent with the public interest. Id. at 1 (citing 21 U.S.C. 
823(g)(1),\1\ 824(a)(4)), 2.
---------------------------------------------------------------------------

    \1\ Effective December 2, 2022, the Medical Marijuana and 
Cannabidiol Research Expansion Act, Public Law 117-215, 136 Stat. 
2257 (2022) (Marijuana Research Amendments or MRA), amended the 
Controlled Substances Act (CSA) and other statutes. Relevant to this 
matter, the MRA redesignated 21 U.S.C. 823(f), cited in the OSC, as 
21 U.S.C. 823(g)(1). Accordingly, this Decision cites to the current 
designation, 21 U.S.C. 823(g)(1), and to the MRA-amended CSA 
throughout.
---------------------------------------------------------------------------

    A hearing was held before DEA Administrative Law Judge Paul E. 
Soeffing (ALJ), who, on September 8, 2023, issued his Recommended 
Rulings, Findings of Fact, Conclusions of Law, and Decision 
(Recommended Decision or RD), which recommended revocation of 
Respondent's registration. RD, at 45. Respondent did not file 
Exceptions to the RD. Having reviewed the entire record, the Agency 
adopts and hereby incorporates by reference the entirety of the ALJ's 
rulings, credibility findings,\2\ findings of fact, conclusions of law, 
sanctions analysis, and recommended sanction as found in the RD.
---------------------------------------------------------------------------

    \2\ The Agency adopts the ALJ's summary of each of the 
witnesses' testimonies as well as the ALJ's assessment of each of 
the witnesses' credibility. See RD, at 2-22. The Agency agrees with 
the ALJ that the testimony from the DEA Diversion Investigator (DI), 
which was primarily focused on the introduction of the Government's 
documentary evidence, was generally consistent, without indication 
of any animosity towards Respondent, and thus was fully credible and 
warranted substantial weight. Id. at 4-5. The Agency also agrees 
with the ALJ that the testimony from the DEA Special Agent (SA), 
which was primarily focused on the introduction of the Government's 
documentary evidence and how the undercover visits were conducted, 
was generally consistent, without indication of any animosity 
towards Respondent, and thus was fully credible and warranted 
substantial weight. Id. at 8. Finally, the Agency agrees with the 
ALJ that the testimony from the Government's expert witness, Dr. 
Brian Durkin, D.O., which was focused on the New York standard of 
care and Respondent's prescribing to the Undercover Officer, 
presented an objective analysis that was internally consistent, 
logically persuasive, credible, reliable, and warranted significant 
weight. Id. at 22.
---------------------------------------------------------------------------

I. Findings of Fact

New York Standard of Care

    Dr. Brian Durkin, D.O., testified for the Government as an expert 
in the area of pain management and the standard of care for prescribing 
controlled substances in the state of New York. RD, at 9; Tr. 367.\3\ 
Dr. Durkin practices as an anesthesiologist and pain management 
specialist and testified that his expert opinion regarding the standard 
of care in this case is informed by his experiences, the experiences of 
his colleagues (including physicians and advanced practice providers), 
and the medical societies that he participates in or leads. RD, at 8, 
13; Tr. 363, 499.\4\ Dr. Durkin also testified that New York has 
codified the standards for the prescribing of opioids. RD, at 13; Tr. 
500.
---------------------------------------------------------------------------

    \3\ On cross-examination, Dr. Durkin testified that the standard 
of care varies geographically based on the specialists available to 
patients that live in a given locality; nonetheless, all 
practitioners in New York are required to complete an opioid 
prescribing course every two years that establishes guidelines for 
prescribing opioids in New York. RD, at 12-13; Tr. 497-98, 501-02. 
When asked to clarify his testimony regarding a regional standard of 
care, Dr. Durkin testified that the regional aspect was confined to 
the availability of specialists, and provided as an example that a 
general practitioner could be competent to deliver a baby in a rural 
community without obstetricians but is likely not competent and 
should not offer obstetric services in an urban environment with 
many local obstetricians. RD, at 13 n.21; Tr. 554-56. Regarding the 
current matter, Dr. Durkin opined that Respondent's care fell below 
the standard of care in every New York region and community 
``because nothing was ever done to address the problem or make a 
correct diagnosis,'' as required throughout the state. RD, at 13 
n.21; Tr. 556-57.
    \4\ For Dr. Durkin's full qualifications, see Government Exhibit 
(GX) 19; RD, at 8-9.
---------------------------------------------------------------------------

    According to Dr. Durkin, under the standard of care in New York, a 
practitioner must establish a patient and provider relationship to 
prescribe controlled substances and must have a legitimate medical 
reason to prescribe opioids. RD, at 9; Tr. 368, 383. Further, the 
practitioner must form a diagnosis and treatment plan after reviewing 
the patient's full medical history,\5\ conducting a physical 
examination, and ordering any necessary tests or referring the patient 
to a specialist. RD, at 9; Tr. 368, 370-71. Dr. Durkin explained that a 
proper physical examination requires an initial observation of the 
patient's presentation and functionality, followed by a targeted 
physical examination related to the patient's pain complaint, including 
tests aimed at diagnosing specific causes of pain. RD, at 10; Tr. 377-
78, 494-95, 550. According to Dr. Durkin, a physical examination should 
be conducted during every encounter, including initial visits, follow-
up visits, telehealth visits, and in-person visits. RD, at 10; Tr. 384. 
Dr. Durkin testified that an in-person physical examination is more 
involved than a virtual examination, but the physician can still 
examine the patient virtually, for example, by listening to the 
patient's voice to see if his words are slurred and observing the 
patient's state of mind. RD, at 10, 20; Tr. 383-84, 419-20.
---------------------------------------------------------------------------

    \5\ Dr. Durkin testified that a full medical history includes 
past medical history, past surgical history, a social history, and 
family history; a full medical history also sometimes focuses on a 
particular part of the body depending on the complaint of pain, but 
is always aimed at assessing a patient's overall health. RD, at 9; 
Tr. 369-70. Dr. Durkin also testified that a practitioner needs 
records from previous treating providers to make sure that the 
treatment is not repetitive and to make sure that the patient is 
treated safely, effectively, and cost effectively. RD, at 9 n.18; 
Tr. 370.
---------------------------------------------------------------------------

    Regarding documentation, Dr. Durkin testified that the standard of 
care requires that practitioners document history and physical 
examinations in patient records to: 1) guide the diagnosis, treatment 
plan, and any decisions about diagnostic testing; 2) make the patient's 
care more efficient and cost-effective; and 3) generate a robust record 
for future providers. RD, at 11; Tr. 378-81. Dr. Durkin also noted that 
the standard of care requires that practitioners not falsify patient 
records. RD, at 9-10; Tr. 549-50.
    Regarding the prescribing of opioids to treat pain, Dr. Durkin 
testified that opioids may be the first line of treatment for acute or 
severe pain, such as pain following surgery, provided that they are 
prescribed for no more than three to seven days. RD, at 11; Tr. 368. In 
contrast, with chronic pain lasting three months or more, there are 
other modalities that are safer and more effective than opioid therapy. 
Id. These modalities should be assessed based on their level of 
invasiveness and risk. RD, at 11; Tr. 369. Dr. Durkin explained that if 
less-invasive options, such as surgery and physical therapy, have 
failed, the practitioner should begin medication management with the 
less risky medications, such as anti-inflammatory drugs and muscle 
relaxants. RD, at 11; Tr. 369, 371-72, 405. If all of these options 
fail, then a practitioner may consider opioid therapy, but the 
practitioner needs to weigh the risks (ranging from mild issues to 
death) and benefits to the patient. Id.
    Dr. Durkin testified that prior to beginning opioid therapy, the 
physician must obtain informed consent by discussing the risks and 
benefits of treatment. RD, at 12; Tr. 374-75, 405. Informed consent 
typically involves a written agreement, signed by the patient (and a 
witness), that outlines the risks, benefits, rules, and guidelines of 
opioid treatment, as well as compliance

[[Page 54048]]

measures that will be utilized to prevent diversion and abuse, such as 
urinalysis and pill counts. RD, at 12, 13; Tr. 374-76, 405, 469-71. Dr. 
Durkin testified that a prescriber must also review a patient's I-STOP 
\6\ data, history of addiction and substance abuse, and family history 
of addiction before prescribing opioids. RD, at 12; Tr. 372-74. 
Finally, practitioners must address any red flags of abuse or diversion 
to ensure that the medications that they prescribe are being used 
safely and legitimately. RD, at 19; Tr. 413-14.
---------------------------------------------------------------------------

    \6\ I-STOP, New York's Prescription Monitoring Program, includes 
a record of controlled substances prescribed to a patient in New 
York. RD, at 6 n. 12, 12; Tr. 372-73. This data is analyzed to 
ensure that patients are not doctor shopping or receiving opioids 
from multiple providers. RD, at 12; Tr. 383.
---------------------------------------------------------------------------

    Regarding follow-up visits, Dr. Durkin testified that a provider 
must assess the effectiveness of the treatment plan, including, (1) 
whether the patient has tried alternative therapies such as physical 
therapy, (2) how the patient is progressing in the treatment plan, and 
(3) the efficacy of any prescribed medications as well as any side 
effects. RD, at 19-20; Tr. 418-19. For opioid medications in 
particular, the provider must also conduct an ongoing risk assessment, 
document functional improvements, and determine whether weaning off or 
increasing the medication is needed. Id.

Respondent's Treatment of the Undercover Officer

March 11, 2021 Visit
    Dr. Durkin reviewed audiovisual recordings of the interactions 
between Respondent and an Undercover Officer (UC), transcripts of the 
recordings, the UC's medical records, and the prescription history for 
the UC. RD, at 13; Tr. 387, 469. The UC first visited Respondent on 
March 11, 2021, complaining of shoulder pain. RD, at 15; Tr. 388-89, 
493; GX 2; GX 3, at 4. The UC reported having pain for ten years, that 
he had not had any diagnostic imaging done, and that he took his 
girlfriend's oxycodone because she had insurance. RD, at 15; Tr. 389; 
GX 1, at 1; GX 2; GX 3, at 4.
    Dr. Durkin testified that a physician acting within the standard of 
care would have made a diagnosis and developed a treatment plan (as 
described above), after conducting a focused physical examination of 
the UC's cervical spine, shoulders, and upper extremities, and ordering 
imaging of those areas. RD, at 15; Tr. 390-91.\7\ Respondent documented 
a very thorough physical examination of the UC--including a full 
vascular, muscular, and neurological examination and range of motion 
testing--but Dr. Durkin's review of the video recording revealed that 
the actual physical examination that Respondent performed was ``[not] 
anywhere close to what [was] documented in the medical record.'' RD, at 
17; Tr. 400; GX 1, at 2-4. According to Dr. Durkin, Respondent's 
examination of the UC appeared to take about twelve seconds, whereas 
the examination documented in the medical file would have taken a 
neurologist ten or fifteen minutes to complete. RD, at 17; Tr. 400-01; 
GX 2; GX 3, at 6. Moreover, while there was a documented pain score in 
the record, Dr. Durkin saw ``no indication that there was a pain score 
asked [about] during the audio visual or in the transcripts.'' Tr. 402; 
see also RD, at 17; GX 1, at 2; GX 2; GX 3, at 3-11. As such, Dr. 
Durkin concluded that the notes in the UC's patient file do not 
accurately reflect what happened during the March 11, 2021 visit. RD, 
at 17; Tr. 401.
---------------------------------------------------------------------------

    \7\ On cross-examination, Dr. Durkin was asked how an uninsured 
patient can afford diagnostic imaging. RD, at 15 n.26; Tr. 509-15. 
Dr Durkin testified that Respondent could have helped the UC find an 
affordable Medicaid plan that would cover imaging or could have 
referred the UC to a university hospital for free or low-cost 
imaging and ``charity care.'' Id.
---------------------------------------------------------------------------

    Regarding Respondent's patient notes from this visit, Dr. Durkin 
testified that the ``Past Medical/Surgical History'' section should 
have detailed any chronic medical problems and past surgeries; however, 
this section in the UC's medical file is blank. RD, at 16; Tr. 391. 
Further, based on the recording of this visit, Respondent did not ask 
the UC about his medical or surgical history, did not request any 
medical files or imaging studies from previous providers, and did not 
order any diagnostic imaging. RD, at 16; Tr. 391-93; GX 1; GX 2; GX 3, 
at 3-10. Dr. Durkin testified that this is ``Medicine 101'' and that 
the ``heart and soul of medicine is getting a history, a physical 
examination, and confirmation with testing.'' RD, at 16; Tr. 392-93. 
Regarding a patient's history in particular, providers need to know 
what treatments the patient has tried, whether they have worked, and 
whether non-opioid medications have been trialed. RD, at 16; Tr. 392-
394, 396.\8\
---------------------------------------------------------------------------

    \8\ On cross-examination, when asked about the UC having a 
fictious identity with no prior medical history or records, Dr. 
Durkin opined that this lack of history and records should have 
generated additional red flags of abuse or diversion. RD, at 16 
n.27; Tr. 502-04.
---------------------------------------------------------------------------

    As for the ``Medications'' and ``Allergies'' sections of 
Respondent's patient notes from the initial visit, Dr. Durkin noted 
that these sections are blank in the UC's medical file despite the UC 
telling Respondent: (1) that he had been taking oxycodone 20 mg (which 
was prescribed to his girlfriend) several times a day; and (2) that he 
is allergic to penicillin and sulfa antibiotics. RD, at 16; Tr. 395-
398, 549; GX 1, at 1-2; GX 2; GX 3, at 4-5. As for the ``Social 
History'' section, Dr. Durkin testified that Respondent did not ask the 
UC about his history of smoking or alcohol during the initial visit but 
Respondent documented that the UC does not use alcohol or tobacco. RD, 
at 16; Tr. 398; GX 1, at 2; GX 2; GX 3, at 11. Further, despite the UC 
reporting his use of oxycodone (not prescribed to him) three weeks 
prior to the visit, the ``Social History'' section indicates that the 
UC was not using drugs. RD, at 16; Tr. 399-400; GX 1, at 2; GX 2; GX 3, 
at 4.
    Regarding the ``Assessment'' section of the UC's patient file, Dr. 
Durkin testified that this is where the ``working diagnosis'' should be 
located. RD, at 17-18; Tr. 403. For a patient complaining of chronic 
shoulder pain, Dr. Durkin explained that an appropriate diagnosis based 
solely on a history and physical examination would be chronic shoulder 
pain or acute shoulder pain. RD, at 18; Tr. 403. However, Respondent 
documented that the UC had a herniated disc and lumbar radiculopathy, 
which are diagnoses that cannot be made without imaging, or justified 
by the limited physical examination that Respondent conducted; Dr. 
Durkin therefore concluded that these assessments do not make sense. 
RD, at 18, 20; Tr. 403-04, 423-24; GX 1, at 4. Dr. Durkin further noted 
that while the UC only complained of shoulder pain, the ``Assessment'' 
section references back and leg pain with no mention of shoulder pain 
or a working diagnosis related to the shoulder pain. RD, at 18; Tr. 
404. As such, Dr. Durkin concluded that no steps were taken to hone in 
on an actual diagnosis. Id.
    Overall, Dr. Durkin opined that Respondent's prescribing of 90 
tablets of oxycodone 10 mg to the UC on the UC's initial March 11, 2021 
visit was ``clearly outside the bounds of legitimate prescribing of 
opioids.'' RD, at 19; Tr. 408; see GX 1, at 4. Dr. Durkin testified 
that Respondent's diagnosis of the UC did not resemble the UC's 
complaint or justify opioid therapy, despite Respondent's attempts to 
generate inaccurate paperwork to justify the prescribing. Id. Dr. 
Durkin further testified that issuing an opioid prescription without an 
established diagnosis is outside the standard of care and that the 
oxycodone prescription issued to the UC was not issued for a legitimate 
medical purpose by a

[[Page 54049]]

practitioner acting within the normal course of professional practice. 
RD, at 19; Tr. 408-09, 415. Dr. Durkin noted that the UC presented 
himself as a high-risk patient by admitting to using opioids that were 
not prescribed to him, as well as presenting with other concerning 
factors such as his age and lack of documented treatment history, yet 
Respondent failed to conduct a sufficient risk assessment. RD, at 19; 
Tr. 409-11. Additionally, Respondent completely ignored red flags of 
abuse and diversion and therefore disregarded the risks associated with 
prescribing oxycodone to the UC. Id. Dr. Durkin also testified that 
Respondent failed to obtain informed consent from the UC for 
prescribing opioids because he failed to discuss the risks of opioids, 
possible interactions with other substances, and proper storage and 
disposal, and failed to advise the UC to discontinue the opioids if 
they were not effective. RD, at 18-19; Tr. 405-406.\9\
---------------------------------------------------------------------------

    \9\ On cross-examination, Dr. Durkin was asked whether his 
opinions would change if the UC had filled out an intake form or 
pain management agreement that was not included in the files that he 
reviewed. RD, at 14-15; Tr. 469, 474-76, 479-80, 534-35, 546-49, 
551-53, 481-87. Dr. Durkin testified that these documents would not 
change his opinions. Id. Although intake forms can be a good 
starting point to initiate a patient visit, they do not absolve a 
physician of the duty to have the necessary discussions with his 
patient to establish a diagnosis or treatment plan. RD, at 14-15; 
Tr. 479-80, 534-35. And if a patient had filled out a pain 
management agreement prior to the visit that the physician did not 
discuss with the patient during the visit, it would generate an 
additional red flag because it would indicate that the practice was 
prescribing opioids readily. RD, at 15; Tr. 548, 552-53. Moreover, 
the Agency may infer from Respondent's failure to produce these 
forms that they would not be supportive of his case. Pharmacy Drs. 
Enters., 83 FR 10876, 10899 (2018) (``[W]hen a party has relevant 
evidence within his control which he fails to produce, that failure 
gives rise to an inference that the evidence is unfavorable to 
him.''); UAW v. NLRB, 459 F.2d 1329, 1338 (D.C. Cir. 1972); 
Huthnance v. DC, 722 F.3d 371, 378 (D.C. Cir. 2013).
---------------------------------------------------------------------------

Follow-Up Visits (April 2021-October 2021)
    Regarding the UC's follow-up visit to Respondent on April 8, 2021, 
Dr. Durkin testified that he would expect to see in the ``History of 
Present Illness'' section of the medical file an assessment of the UC's 
functional gains and improvements related to the treatment plan, 
whether the UC's condition had worsened, and how the UC was doing since 
the last visit. RD, at 20; Tr. 420-21. However, Dr. Durkin testified 
that the visit was very brief, lasting approximately one minute, and 
Respondent's examination of the UC was only ``a quick look at the 
patient as he popped his head in the room.'' RD, at 20; Tr. 420. Dr. 
Durkin testified that despite this, the notes in the ``History of 
Present Illness'' section are, again, far more extensive than what 
actually occurred during the visit and the patient record does not 
accurately reflect the visit. RD, at 20; Tr. 421-22; GX 1, at 6-9; GX 
4, GX 5, at 1-2. According to Dr. Durkin, although the patient file 
indicates that a thorough examination and pain assessment took place, 
including notes of symptoms that were not discussed, the actual April 
8, 2021 visit only consisted of a ``how are you doing, we'll see you 
next month[,] . . . I'll send in your prescription refills.'' RD, at 
20; Tr. 421-22; GX 1, at 6-8; GX 4; GX 5, at 1-2. In addition to 
continuing to include the unsupported diagnoses of herniated discs and 
lumbar radiculopathy, the medical records also falsely indicate that 
Respondent checked I-STOP, executed an opioid agreement with the UC, 
discussed physical therapy, and reviewed the pain management policies 
of Respondent's practice, as well as the expectations of opioid 
treatment and treatment goals. RD, at 20-21; Tr. 423-26; GX 1, at 9; GX 
4; GX 5, at 1-2.
    Dr. Durkin testified that Respondent did not obtain the UC's 
informed consent for continued opioid treatment and that Respondent 
could not have adequately examined the UC to justify prescribing 
opioids during this one-minute visit. RD, at 21; Tr. 424, 426-27. 
Ultimately, Dr. Durkin opined that the prescription for 90 tablets of 
oxycodone 10 mg issued by Respondent to the UC on April 8, 2021, was 
not issued for a legitimate medical purpose by a practitioner acting 
within the normal course of professional practice. RD, at 21; Tr. 427; 
see GX 1, at 9.
    Regarding the UC's approximately monthly follow-up visits (both in-
person and via telehealth) to Respondent through October 2021, Dr. 
Durkin again observed concerning deficiencies and contradictions 
between the recordings and the medical records similar to his concerns 
with the initial visit. RD, at 21-22; Tr. 427-462; GX 1, at 10-26; GX 
6; GX 7, at 1-3; GX 8; GX 9, at 1-2; GX 10; GX 11; GX 12; GX 13, at 1-
5; GX 14; GX 15; see also GX 17, at 1, 5, 6, 9, 10, 12. Ultimately, Dr. 
Durkin opined that the prescriptions issued by Respondent to the UC, 
each for 90 tablets of oxycodone 10 mg, were not issued for a 
legitimate medical purpose by a practitioner acting within the normal 
course of professional practice. RD, at 21-22.
    In sum, based on his review of the recordings and the related 
medical records of the UC's visits with Respondent, Dr. Durkin opined 
that all of the prescriptions issued by Respondent to the UC for 
oxycodone were not issued for a legitimate medical purpose by a 
practitioner acting within the normal course of professional practice. 
RD, at 22; Tr. 461. Dr. Durkin further opined that Respondent's 
prescribing of oxycodone to the UC was likely to cause harm to the UC 
and fell below the standard of care for a practitioner in New York. RD, 
at 22; Tr. 462.
    Respondent offered no testimony or documentary evidence and did not 
present a case-in-chief. RD, at 22.

II. Discussion

A. The Five Public Interest Factors

    Under the Controlled Substances Act (CSA), ``[a] registration . . . 
to . . . dispense a controlled substance . . . may be suspended or 
revoked by the Attorney General upon a finding that the registrant . . 
. has committed such acts as would render his registration under 
section 823 of this title inconsistent with the public interest as 
determined under such section.'' 21 U.S.C. 824(a). In making the public 
interest determination, the CSA requires consideration of the following 
factors:

    (A) The recommendation of the appropriate State licensing board 
or professional disciplinary authority.
    (B) The [registrant's] experience in dispensing, or conducting 
research with respect to controlled substances.
    (C) The [registrant's] conviction record under Federal or State 
laws relating to the manufacture, distribution, or dispensing of 
controlled substances.
    (D) Compliance with applicable State, Federal, or local laws 
relating to controlled substances.
    (E) Such other conduct which may threaten the public health and 
safety.

21 U.S.C. 823(g)(1).
    The Agency considers these public interest factors in the 
disjunctive. Robert A. Leslie, M.D., 68 FR 15227, 15230 (2003). Each 
factor is weighed on a case-by-case basis. Morall v. Drug Enf't Admin., 
412 F.3d 165, 173-74 (D.C. Cir. 2005). Any one factor, or combination 
of factors, may be decisive. David H. Gillis, M.D., 58 FR 37507, 37508 
(1993).
    The Government has the burden of proof in this proceeding. 21 CFR 
1301.44. While the Agency has considered all of the public interest 
factors in 21 U.S.C. 823(g)(1), the Government's evidence in support of 
its prima facie case for revocation of Respondent's registration is 
confined to Factors B and D. RD, at 25; see also id. at 25 n.32 
(finding that Factors A, C, and E do not weigh for or against 
revocation).
    Having reviewed the record and the RD, the Agency agrees with the 
ALJ,

[[Page 54050]]

adopts the ALJ's analysis, and finds that the Government's evidence 
satisfies its prima facie burden of showing that Respondent's continued 
registration would be ``inconsistent with the public interest.'' 21 
U.S.C. 824(a)(4); RD, at 22-41.

B. Factors B and D

    Evidence is considered under Public Interest Factors B and D when 
it reflects compliance (or non-compliance) with laws related to 
controlled substances and experience dispensing controlled substances. 
See Sualeh Ashraf, M.D., 88 FR 1095, 1097 (2023); Kareem Hubbard, M.D., 
87 FR 21156, 21162 (2022). In the current matter, the Government has 
alleged that Respondent violated numerous Federal and State laws 
regulating controlled substances. OSC/ISO, at 1-2. Specifically, 
Federal law requires that ``[a] prescription for a controlled substance 
to be effective must be issued for a legitimate medical purpose by an 
individual practitioner acting in the usual course of his professional 
practice.'' 21 CFR 1306.04(a).\10\ As for state law, New York 
regulations also provide that a controlled substance may only be 
prescribed by ``[a] practitioner, in good faith, and in the course of 
his or her professional practice.'' N.Y. Pub. Health Law section 
3331(2); \11\ see also N.Y. Comp. Codes R. & Regs. tit. 10, sections 
80.62(a) (practitioners ``in the course of their professional practice, 
may dispense, administer or prescribe controlled substances for 
legitimate medical purposes or treatment . . . ''), 80.65 
(prescriptions for controlled substances ``shall be issued for 
legitimate medical purposes only''), 94.2(e)(2) (a physician assistant 
may only prescribe controlled substances ``in good faith and acting 
within his or her lawful scope of practice''). Further, New York state 
law provides that a practitioner's license ``may be revoked . . . in 
whole or in part upon a finding that the licensee or certificate holder 
has . . . falsified any [required] application, report, or record'' or 
``failed to maintain effective control against diversion of controlled 
substances . . . .'' N.Y. Pub. Health Law section 3390(1), (5).
---------------------------------------------------------------------------

    \10\ The Agency need not adjudicate the criminal violations 
alleged in the instant OSC/ISO. Ruan v. United States, 142 S. Ct. 
2,370 (2022) (decided in the context of criminal proceedings).
    \11\ A ``practitioner'' is defined as ``[a] physician . . . or 
other person licensed, or otherwise permitted to dispense, 
administer or conduct research with respect to a controlled 
substance in the course of a licensed professional practice . . . 
.'' N.Y. Pub. Health Law section 3302(27).
---------------------------------------------------------------------------

    In the current matter, the Agency agrees with the ALJ's analysis 
that Respondent repeatedly issued controlled substance prescriptions 
outside the usual course of professional practice and not for a 
legitimate medical purpose because, as detailed above, Respondent 
failed to adequately examine, evaluate, and diagnose the UC to 
medically justify prescribing him controlled substances, and failed to 
address red flags of abuse and/or diversion before issuing the 
prescriptions. RD, at 27-28. Further, Respondent repeatedly and 
egregiously falsified the UC's medical records, documenting physical 
examinations, compliance measures, and patient-doctor discussions that 
did not occur. Id. As Respondent's conduct displays clear violations of 
the federal and state regulations described above, the Agency agrees 
with the ALJ and hereby finds that Respondent repeatedly violated 
federal and state law relating to controlled substances. RD, at 41. 
Accordingly, the Agency agrees with the ALJ and finds that Factors B 
and D weigh in favor of revocation of Respondent's registration and 
thus finds Respondent's continued registration to be inconsistent with 
the public interest in balancing the factors of 21 U.S.C. 823(g)(1).

III. Sanction

    Where, as here, the Government has established sufficient grounds 
to revoke Respondent's registration, the burden shifts to the 
registrant to show why he can be entrusted with the responsibility 
carried by a registration. Garret Howard Smith, M.D., 83 FR 18882, 
18904 (2018). When a registrant has committed acts inconsistent with 
the public interest, he must both accept responsibility and demonstrate 
that he has undertaken corrective measures. Holiday CVS, L.L.C., dba 
CVS Pharmacy Nos 219 and 5195, 77 FR 62316, 62339 (2012). Trust is 
necessarily a fact-dependent determination based on individual 
circumstances; therefore, the Agency looks at factors such as the 
acceptance of responsibility, the credibility of that acceptance as it 
relates to the probability of repeat violations or behavior, the nature 
of the misconduct that forms the basis for sanction, and the Agency's 
interest in deterring similar acts. See, e.g., Robert Wayne Locklear, 
M.D., 86 FR 33738, 33746 (2021).
    Here, although Respondent requested a hearing and submitted a 
prehearing statement, Respondent ultimately offered no testimony or 
documentary evidence and did not present a case-in-chief. Respondent's 
failure to demonstrate any remorse for his actions or offer any 
assurances about his future compliance weigh strongly against continued 
registration because his conduct did much to diminish his credibility 
with the Agency.
    In addition to acceptance of responsibility, the Agency considers 
both specific and general deterrence when determining an appropriate 
sanction. Daniel A. Glick, D.D.S., 80 FR 74800, at 74810 (2015). In 
this case, the Agency agrees with the ALJ that the interests of 
specific deterrence weigh in favor of revoking Respondent's 
registration. RD, at 44; GX 1-17. Further, the Agency agrees with the 
ALJ that the interests of general deterrence also support revocation, 
as a lack of sanction in the current matter would send a message to the 
registrant community that prescribing controlled substances without 
conducting and documenting even the most basic treatment-related 
evaluations and examinations can be overlooked or excused. RD, at 44.
    Moreover, the Agency agrees with the ALJ that Respondent's actions 
were egregious. Id. at 43-44. Not only did Respondent fail to complete 
all of the necessary components of a proper medical examination to 
justify the prescribing of opioids, he flagrantly falsified the UC's 
medical record presumably to evade government scrutiny. Notably, 
Respondent documented a detailed evaluation and examination of the UC 
that did not occur. Id. at 44. This indicates that Respondent was well 
acquainted with his professional and legal obligations, yet chose to 
disregard them, despite the serious dangers the prescribed controlled 
substances posed to the UC, an admitted abuser, and the community. 
Further, Respondent fabricated diagnoses that were neither tied to the 
UC's initial complaint nor supported by any imaging that would be 
necessary to reach such diagnoses. In this case, the Agency believes 
that revocation of Respondent's registration would deter Respondent and 
encourage the general registrant community to take caution when 
prescribing controlled substances and ensure that their medical records 
are thorough and accurate.
    In sum, Respondent has not offered any credible evidence on the 
record to rebut the Government's case for revocation of his 
registration and Respondent has not demonstrated that he can be 
entrusted with the responsibility of registration. RD, at 45. 
Accordingly, the Agency will order that Respondent's registration be 
revoked.

Order

    Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 
U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. 
MG1185277 issued

[[Page 54051]]

to Michael Gore, P.A. Further, pursuant to 28 CFR 0.100(b) and the 
authority vested in me by 21 U.S.C. 823(g)(1), I hereby deny any 
pending applications of Michael Gore, P.A., to renew or modify this 
registration, as well as any other pending application of Michael Gore, 
P.A., for additional registration in New York. This Order is effective 
July 29, 2024.

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
June 21, 2024, by Administrator Anne Milgram. That document with the 
original signature and date is maintained by DEA. For administrative 
purposes only, and in compliance with requirements of the Office of the 
Federal Register, the undersigned DEA Federal Register Liaison Officer 
has been authorized to sign and submit the document in electronic 
format for publication, as an official document of DEA. This 
administrative process in no way alters the legal effect of this 
document upon publication in the Federal Register.

Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2024-14195 Filed 6-27-24; 8:45 am]
BILLING CODE 4410-09-P